| Old Articles: <Older 801-810 Newer> |
 |
The Motley Fool January 30, 2004 Rick Aristotle Munarriz |
CNET Back in Black The CNET model keeps rocking along towards viability.  |
BusinessWeek February 9, 2004 Gene G. Marcial |
The Buzz On Honeywell Many analysts are sour on Honeywell International, but some investors are buying shares because they smell a takeover. Who might buy the world leader in aircraft electronics and small jet engines?  |
BusinessWeek February 9, 2004 Gene G. Marcial |
Telik's Promising Tumor Treatments Telik, which develops drugs for cancer -- mainly chemotherapy-resistant solid tumors -- and diabetes may be the next biotech buyout. So says Mark Monane of investment outfit Needham, who identified Esperion Therapeutics in early December as buyout bait.  |
BusinessWeek February 9, 2004 Gene G. Marcial |
Envisioning A Buyout For Bioenvision What's George Soros buying? In biotech, he has accumulated 27% of Bioenvision, a little-known biopharma. Other investors: OrbiMed Advisors, with 8%, and Deutsche Bank, with nearly 5%.  |
InternetNews January 29, 2004 Janis Mara |
DoubleClick Beats Predictions, Raises 2004 Guidance The online ad technology provider appears to have recovered from the dot-com bust.  |
The Motley Fool January 29, 2004 W.D. Crotty |
Altria Is Smokin' Philip Morris and Kraft's parent company releases stellar numbers for 2003.  |
The Motley Fool January 29, 2004 Dave Marino-Nachison |
Hoover Sucks Up Profit Maytag hopes to reenergize its ailing floor-care division starting in Q2.  |
The Motley Fool January 29, 2004 Matt Thurmond |
Altera's High-Tech Battle Altera and Xilinx duke it out in the ring of programmable logic devices.  |
The Motley Fool January 29, 2004 Jeff Hwang |
Is JDS Uniphase Back? A definite rebound in revenues just may justify the recent run-up.  |
The Motley Fool January 29, 2004 Seth Jayson |
Reebok Runs Right The No. 2 sports shoe maker posts good gains.  |
| <Older 801-810 Newer> Return to current articles. |